- Home
- MOBX vs TENX Comparison
MOBX vs TENX Comparison
Compare MOBX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- TENX
- Stock Information
- Founded
- MOBX 2020
- TENX 1967
- Country
- MOBX United States
- TENX United States
- Employees
- MOBX N/A
- TENX N/A
- Industry
- MOBX
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- TENX Health Care
- Exchange
- MOBX Nasdaq
- TENX Nasdaq
- Market Cap
- MOBX 52.0M
- TENX 56.2M
- IPO Year
- MOBX N/A
- TENX N/A
- Fundamental
- Price
- MOBX $0.47
- TENX $9.39
- Analyst Decision
- MOBX
- TENX Strong Buy
- Analyst Count
- MOBX 0
- TENX 2
- Target Price
- MOBX N/A
- TENX $17.00
- AVG Volume (30 Days)
- MOBX 1.8M
- TENX 83.4K
- Earning Date
- MOBX 12-18-2025
- TENX 11-12-2025
- Dividend Yield
- MOBX N/A
- TENX N/A
- EPS Growth
- MOBX N/A
- TENX N/A
- EPS
- MOBX N/A
- TENX N/A
- Revenue
- MOBX $10,984,000.00
- TENX N/A
- Revenue This Year
- MOBX N/A
- TENX N/A
- Revenue Next Year
- MOBX N/A
- TENX N/A
- P/E Ratio
- MOBX N/A
- TENX N/A
- Revenue Growth
- MOBX 180.13
- TENX N/A
- 52 Week Low
- MOBX $0.40
- TENX $4.63
- 52 Week High
- MOBX $2.47
- TENX $9.70
- Technical
- Relative Strength Index (RSI)
- MOBX 32.53
- TENX 75.09
- Support Level
- MOBX $0.43
- TENX $7.30
- Resistance Level
- MOBX $0.47
- TENX $9.70
- Average True Range (ATR)
- MOBX 0.06
- TENX 0.50
- MACD
- MOBX -0.00
- TENX 0.25
- Stochastic Oscillator
- MOBX 18.40
- TENX 89.68
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.